AWD 12343
Latest Information Update: 13 Mar 2002
Price :
$50 *
At a glance
- Originator elbion
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 13 Mar 2002 Discontinued - Preclinical for Respiratory tract disorders in Germany (unspecified route)
- 01 Jul 2000 Preclinical development for Respiratory tract disorders in Germany (Unknown route)
- 06 Jun 2000 Preclinical development for Allergy in Germany (Unknown route)